Exclusive Summary

• - Mature generic: originator approved in 2001, key patents expired 2013–2017, with broad global generic uptake.
• - Clear demand: invasive candidiasis and aspergillosis together approach ~1 million cases annually, driven by ICU, oncology, and transplant populations.
• - First-line status: endorsed by IDSA/ESCMID and CDC (incl. Candida auris) as frontline therapy for invasive candidiasis.
• - Supply/compliance: US-FDA GMP plus US registration in progress enables reliable second-source positioning for a sterile injectable.
• - Cost advantage: typically 70–90% below originator in multi-source markets, fitting tenders and hospital procurement.